Publications

Publications

Filter Results: (249) Arrow Down

Show Results For

← Page 5 of 249 Results →
  • 04 Feb 2014
  • First Look

First Look: February 4

products at reasonable prices and runs a highly popular advertising campaign that spoofs current events. It offers its farmers 80% of the consumer's dollar for milk, compared with 35% to 40% typical in some Western markets. Amul's... View Details
Keywords: Sean Silverthlorne
  • 28 Jul 2015
  • First Look

First Look: July 28, 2015

come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the U.S. market. Gilead had to decide how... View Details
Keywords: Carmen Nobel
  • 2023
  • Article

Dynamic HTA for Digital Health Solutions: Opportunities and Challenges for Patient-Centered Evaluation

By: Jan B. Brönneke, Annika Herr, Simon Reif and Ariel D. Stern
Germany’s 2019 Digital Healthcare Act (Digitale-Versorgung-Gesetz, or DVG) created a number of opportunities for the digital transformation of the health care delivery system. Key among these was the creation of a reimbursement pathway for patient-centered digital... View Details
Keywords: Digital Transformation; Applications and Software; Product Development; Insurance; Policy; Health Industry; Germany
Related
  • 20 Nov 2007
  • First Look

First Look: November 20, 2007

  Working PapersNone this week   PublicationsFinancial Development, Bank Ownership, and Growth. Or, Does Quantity Imply Quality? Author:Shawn Cole Periodical:Review of Economics and Statistics (forthcoming) Abstract In 1980, India nationalized its large private banks.... View Details
Keywords: Martha Lagace
  • March 2008
  • Case

Novartis AG: Science-Based Business

By: H. Kent Bowen and Courtney Purrington
Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in sales in 2007. Pharmaceuticals account for slightly over $24B of that total. In 2007,... View Details
Keywords: Innovation and Invention; Resource Allocation; Product Development; Partners and Partnerships; Research and Development; Science-Based Business; Pharmaceutical Industry
Related
  • Web

Overview - MBA

in neglected diseases, the provision of life-saving drugs to disadvantaged patients and those in the developing world, and the pricing of medicines. Program Brochure View Details
  • June 2024
  • Article

Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices

By: Jason Shafrin, Jaehong Kim, Joshua T. Cohen, Louis P. Garrison, Dana A. Goldman, Jalpa A. Doshi, Joshua Krieger, Darius N. Lakdawalla, Peter J. Neumann, Charles E. Phelps, Melanie D. Whittington and Richard Willke
This study argues that value assessment conducted from a societal perspective should rely on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein. Recently developed value assessment inventories—such as the Second Panel on Cost-Effectiveness’s... View Details
Keywords: Health Care and Treatment; Valuation; Cost vs Benefits; Society
Related
  • 16 Jul 2008
  • Op-Ed

What Should Employers Do about Health Care?

frequently in search of a better deal, which has meant that their employees needed to switch as well. They have tried to pare back covered services, thrown up barriers to expensive drugs and treatments, and recently, begun to pass more... View Details
Keywords: by Michael E. Porter, Elizabeth O. Teisberg & Scott Wallace; Health
  • 14 Nov 2017
  • First Look

New Research and Ideas: November 14, 2017

Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=53507 forthcoming Journal of Financial Economics Bubbles for Fama By: Greenwood, Robin, Andrei Shleifer, and Yang You Abstract—We evaluate Eugene Fama's claim that stock View Details
Keywords: Carmen Nobel
  • 14 Jul 2006
  • Op-Ed

The Case for Consumer-Driven Medicaid

The Medicaid program provides a much needed health insurance safety net for 52 million of our nation's poor and medically needy, but its price tag threatens the financial stability of the states, growing 9.5 percent in 2004 alone—far in... View Details
Keywords: by Regina E. Herzlinger
  • Web

Faculty & Advisors - MBA

valued at over $12 billion. At Underscore VC, she invested in fast growing B2B software startups, including life sciences tech products used by leading biopharma companies across the drug development cycle from R&D to commercial stages.... View Details
  • 05 Sep 2023
  • Book

Failing Well: How Your ‘Intelligent Failure’ Unlocks Your Full Potential

In the 1990s, after drugmaker Eli Lilly spent more than a decade and millions of dollars developing the new drug Alimta to treat lung cancer, the medication came up short in effectively treating cancer in expanded trials. While the... View Details
Keywords: by Michael Blanding
  • Web

Marketing - Faculty & Research

experiment. Featured Case Hometown Foods: Changing Price Amid Inflation Case By: Julian De Freitas, Jeremy Yang, and Das Narayandas During the early part of the 2021 Covid-19 pandemic, Hometown Foods, a large seller of flour-based... View Details
  • Research Summary

Regulatory Change/Business-Government Relations

“Sources of Learning Heterogeneity: Discontinuous Regulatory Shock and its Impact on Organizational Search Behaviors”

Co-authoring with Jerry Kim, in this study I look at how discontinuous regulatory shock shapes organizational... View Details

Keywords: Business ＆ Government Relations; Regulations; Regulatory Capture; Pharmaceutical Industry; United States
  • 10 Oct 2007
  • First Look

First Look: First Look: October 10

defeated by a less reformist coalition. Stock prices of government-controlled companies that had been slated for definite privatization by the BJP dropped by 3.5 percent relative to private firms. Surprisingly, government-controlled... View Details
Keywords: Martha Lagace
  • 30 Jun 2022
  • HBS Case

Peloton Changed the Exercise Game. Can the Company Push Through the Pain?

demand, which led to shipment delays, followed by pricing confusion and a series of public relations bungles—just as the pandemic eased and people began returning to gyms. Peloton scrambled by recalling items and dropping prices, amid an... View Details
Keywords: by Lane Lambert; Media & Broadcasting; Health; Bicycle
  • 05 Dec 2017
  • First Look

First Look at New Research and Ideas, December 5, 2017

conformity comes at a steep price for our careers and personal lives. When we mindlessly accept rules and norms rather than questioning and constructively rebelling against them, we ultimately end up stuck and unfulfilled. As leaders, we... View Details
Keywords: Sean Silverthorne
  • Web

Health Care - Faculty & Research

Proceedings High out-of-pocket (OOP) prices for prescription drugs create financial difficulties for patients, and cost-related underuse of medications can adversely patient health. Simultaneously, many... View Details
  • 25 Jul 2023
  • Research & Ideas

Could a Business Model Help Big Pharma Save Lives and Profit?

With Hepatitis C running rampant in Egypt in 2012, Clifford Samuel, then of California-based Gilead Sciences, convened a series of urgent meetings with Egyptian government officials, doctors, and patients. His goal? To make Gilead’s lifesaving Hepatitis C View Details
Keywords: by Esther Schrader; Pharmaceutical; Health
  • 12 Feb 2008
  • First Look

First Look: February 12, 2007

Moskowitz, and Annette Vissing-Jørgensen Abstract We provide new evidence on the success of long-run risks in asset pricing by focusing on the risks borne by stockholders. Exploiting micro-level household consumption data, we show that... View Details
Keywords: Martha Lagace